Details for New Drug Application (NDA): 213551
✉ Email this page to a colleague
NDA 213551 describes CANGRELOR, which is a drug marketed by Gland and MSN and is included in two NDAs. It is available from one supplier. Additional details are available on the CANGRELOR profile page.
The generic ingredient in CANGRELOR is cangrelor. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the cangrelor profile page.
The generic ingredient in CANGRELOR is cangrelor. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the cangrelor profile page.
Pharmacology for NDA: 213551
| Mechanism of Action | P2Y12 Receptor Antagonists |
| Physiological Effect | Decreased Platelet Aggregation |
Suppliers and Packaging for NDA: 213551
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CANGRELOR | cangrelor | POWDER;INTRAVENOUS | 213551 | ANDA | Gland Pharma Limited | 68083-412 | 68083-412-10 | 10 VIAL, SINGLE-DOSE in 1 CARTON (68083-412-10) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS | Strength | 50MG/VIAL | ||||
| Approval Date: | Aug 11, 2025 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
